USD10
ELVN Shares
About Enliven TherapeuticsEnliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
USD10
ELVN Shares
About Enliven TherapeuticsEnliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$2.32B
OPEN PRICE
$39.29
LOW (1Y)
$13.30
HIGH (1Y)
$40.62
LOW (24H)
$37.72
HIGH (24H)
$39.59
VOLUME (24H)
$1.35M
61.03%
Price history
Time | Price | Change |
|---|---|---|
Today | $39.29 | |
1 Day | $39.00 | |
1 Week | $28.60 | |
1 Month | $29.30 | |
1 Year | $19.68 |
Discover more
Popular prediction markets
Popular price predictions
Legal
All securities and investments are offered by Coinbase Capital Markets Corp, member FINRA/SIPC. Securities services offered by Coinbase Capital Markets Corp are separate from digital asset services provided by Coinbase Inc., and any affiliates or crypto asset services provided under MiCA by Coinbase Luxembourg S.A. SIPC does not apply to digital assets or cash held in your Coinbase Inc. account. Additional information about your broker, Coinbase Capital Markets Corp, can be found on FINRA’s BrokerCheck. Execution, clearing and custody of all securities are provided by Apex Clearing Corporation.This page and the content herein is for informational purposes only and does not constitute the provision of investment advice. The customer assumes full responsibility for its trading activity and should consult its advisors for its specific situation. This material is not (i) an offer, or solicitation of an offer, to invest in, or to buy or sell, any interests or shares, or to participate in any investment or trading strategy, (ii) intended to provide accounting, legal, or tax advice, or investment recommendations. The information is believed to be current as of the date indicated and may not be updated or otherwise revised to reflect information that subsequently became available or a change in circumstances after the date of publication. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. Recipients should consult their advisors before making any investment decision.All ticker names are trademarks of their respective holders. Any ticker reference does not imply any affiliation with or endorsement by a third party. Real-time quote and/or trade prices are not sourced from all markets, source: Nasdaq Last Sale. Morningstar data ©2026.
